维普中文期刊产品整合服务
26篇 您的检索式:作者名="Burisch"
    题名 作者 年代 出处 被引量
1Ehealth:Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome显示文摘AIM:To investigate the effects of a low fermentable,oligosaccharides,disaccharides,monosaccharides and polyols diet(LFD)and the probiotic Lactobacillus rhamnosus GG(LGG)in irritable bowel syndrome(IBS).METHODS:Randomised,unblinded controlled trial on the effect of 6-wk treatment with LFD,LGG or a normal Danish/Western diet(ND)in patients with IBS fulfilling Rome III diagnostic criteria,recruited betweenNovember 2009 and April 2013.Patients were required to complete on a weekly basis the IBS severity score system(IBS-SSS)and IBS quality of life(IBS-QOL)questionnaires in a specially developed IBS web selfmonitoring application.We investigated whether LFD or LGG could reduce IBS-SSS and improve QOL in IBS patients.RESULTS:One hundred twenty-three(median age 37years,range:18-74 years),90(73%)females were randomised:42 to LFD,41 to LGG and 40 to ND.A significant reduction in mean±SD of IBS-SSS from baseline to week 6 between LFD vs LGG vs ND was revealed:133±122 vs 68±107,133±122 vs 34±95,P<0.01.Adjusted changes of IBS-SSS for baseline covariates showed statistically significant reduction of IBS-SSS in LFD group compared to ND(IBS-SSS score75;95%CI:24-126,P<0.01),but not in LGG compared to ND(IBS-SSS score 32;95%CI:18-80,P=0.20).IBS-QOL was not altered significantly in any of the three groups:mean±SD in LFD 8±18 vs LGG 7±17,LFD 8±18 vs ND 0.1±15,P=0.13.CONCLUSION:LFD is efficacious for patients with IBS.Natalia Pedersen Nynne Nyboe Andersen Zsuzsanna Végh Lisbeth Jensen Dorit Vedel Ankersen Maria Felding Mette Hestetun Simonsen Johan Burisch Pia Munkholm 2014World Journal of Gastroenterology2014,20,43:16
2Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease显示文摘AIM To investigate the effect of a low-FODMAP diet on irritable bowel syndrome(IBS)-like symptoms in patients with inflammatory bowel disease(IBD).METHODS This was a randomised controlled open-label trial of patients with IBD in remission or with mild-to-moderate disease and coexisting IBS-like symptoms(Rome III) randomly assigned to a Low-FODMAP diet(LFD) or a normal diet(ND) for 6 wk between June 2012 andDecember 2013. Patients completed the IBS symptom severity system(IBS-SSS) and short IBD quality of life questionnaire(SIBDQ) at weeks 0 and 6. The primary end-point was response rates(at least 50-point reduction) in IBS-SSS at week 6 between groups; secondary end-point was the impact on quality of life. RESULTS Eighty-nine patients, 67(75%) women, median age 40, range 20-70 years were randomised: 44 to LFD group and 45 to ND, from which 78 patients completed the study period and were included in the final analysis(37 LFD and 41 ND). There was a significantly larger proportion of responders in the LFD group(n = 30, 81%) than in the ND group(n = 19, 46%);(OR = 5.30; 95%CI: 1.81-15.55, P < 0.01). At week 6, the LFD group showed a significantly lower median IBSSSS(median 115; inter-quartile range [IQR] 33-169) than ND group(median 170, IQR 91-288), P = 0.02. Furthermore, the LFD group had a significantly greater increase in SIBDQ(median 60, IQR 51-65) than the ND group(median 50, IQR 39-60), P < 0.01.CONCLUSION In a prospective study, a low-FODMAP diet reduced IBS-like symptoms and increased quality of life in patients with IBD in remission.Natalia Pedersen Dorit Vedel Ankersen Maria Felding Henrik Wachmann Zsuzsanna Végh Line Molzen Johan Burisch Jens Rikardt Andersen Pia Munkholm 2017World Journal of Gastroenterology2017,23,18:15
3Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet显示文摘AIM: To investigate patient-reported outcomes from, and adherence to, a low FODMAP diet among patients suffering from irritable bowel syndrome and inflammatory bowel disease.METHODS: Consecutive patients with irritable bowel syndrome(IBS) or inflammatory bowel disease(IBD) and co-existing IBS fulfilling the ROME Ⅲ criteria, who previously attended an outpatient clinic for low FODMAP diet(LFD) dietary management and assessment by a gastroenterologist, were invited to participate in a retrospective questionnaire analysis. The questionnaires were sent and returned by regular mail and gathered information on recall of dietarytreatment, efficacy, symptoms, adherence, satisfaction, change in disease course and stool type, and quality of life. Before study enrolment all patients had to sign an informed written consent.RESULTS: One hundred and eighty patients were included, 131(73%) IBS and 49(27%) IBD patients. Median age was 43 years(range: 18-85) and 147(82%) were females. Median follow-up time was 16 mo(range: 2-80). Eighty-six percent reported either partial(54%) or full(32%) efficacy with greatest improvement of bloating(82%) and abdominal pain(71%). The proportion of patients with full efficacy tended to be greater in the IBD group than in the IBS group(42% vs 29%, P = 0.08). There was a significant reduction in patients with a chronic continuous disease course in both the IBS group(25%, P < 0.001) and IBD group(23%, P = 0.002) along with a significant increase in patients with a mild indolent disease course of 37%(P < 0.001) and 23%(P = 0.002), respectively. The proportion of patients having normal stools increased with 41% in the IBS group(P < 0.001) and 66% in the IBD group(P < 0.001). One-third of patients adhered to the diet and high adherence was associated with longer duration of dietary course(P < 0.001). Satisfaction with dietary management was seen in 83(70%) IBS patients and 24(55%) IBD patients. Eightyfour percent of patients lived on a modified LFD, where some foods rich in FODMAPs were reintroduced, and 16% followed the LFD by the book without deviations. Wheat, dairy products, and onions were the foods most often not reintroduced by patients.CONCLUSION: These data suggest that a diet low in FODMAPs is an efficacious treatment solution in the management of functional bowel symptoms for IBS and IBD patients.Louise Maagaard Dorit V Ankersen Zsuzsanna Végh Johan Burisch Lisbeth Jensen Natalia Pedersen Pia Munkholm 2016World Journal of Gastroenterology2016,22,15:8
4Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease显示文摘BACKGROUND The inflammatory bowel diseases(IBD),Crohn’s disease(CD)and ulcerative colitis(UC)are chronic,immune-mediated disorders of the digestive tract.IBD is considered to be a risk factor for developing osteoporosis;however current literature on this matter is inconsistent.AIM To assess prevalence and development of osteoporosis and low bone mineral density(BMD),and its risk factors,in IBD patients.METHODS Systematic review of population-based studies.Studies were identified by electronic(January 2018)and manual searches(May 2018).Databases searched included EMBASE and PubMed and abstracts from 2014-2018 presented at the United European Gastroenterology Week,the European Crohn’s and Colitis Organisation congress,and Digestive Disease Week were screened.Studies were eligible for inclusion if they investigated either the prevalence of osteoporosis or osteopenia and/or risk factors for osteoporosis or low BMD in IBD patients.Studies on children under the age of 18 were excluded.Only population-based studies were included.All risk factors for osteoporosis and low BMD investigated in any included article were considered.Study quality and the possibility of bias were analysed using the Newcastle-Ottawa scale.RESULTS Twelve studies including 3661 IBD patients and 12789 healthy controls were included.Prevalence of osteoporosis varied between 4%-9%in studies including both CD and UC patients;2%-9% in studies including UC patients, and 7%-15% instudies including CD patients. Among healthy controls, prevalence ofosteoporosis was 3% and 10% in two studies. CD diagnosis, lower body massindex (BMI), and lower body weight were risk factors associated withosteoporosis or low BMD. Findings regarding gender showed inconsistent results.CD patients had an increased risk for osteoporosis or low BMD over time, whileUC patients did not. Increased age was associated with decreased BMD, and therewas a positive association between weight and BMI and BMD over time. Greatheterogeneity was found in the included studies in terms of study methodologies,definitions and the assessment of osteoporosis, and only a small number ofpopulation-based studies was available.CONCLUSIONThis systematic review found a possible increase of prevalence of osteoporosis inCD cohorts when compared to UC and cohorts including both disease types.Lower weight and lower BMI were predictors of osteoporosis or low BMD in IBDpatients. The results varied considerably between studies.Sofia Kärnsund Bobby Lo Flemming Bendtsen Jakob Holm Johan Burisch 2020World Journal of Gastroenterology2020,26,35:8
5Ehealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet显示文摘In the present study we report on changes in irritable bowel syndrome-severity scoring system(IBS-SSS)and irritable bowel syndrome-quality of life(IBS-QoL)in 19 IBS patients,aged 18 to 74 years(F/M:14/5),during 12 wk registering their symptoms on the webapplication(www.ibs.constant-care.dk).During a control period of the first 6-wk patients were asked to register their IBS-SSS and IBS-QoL on the web-application weekly without receiving any intervention.Thereafter,low fermentable oligo-,di-,mono-saccharides and polyols(FODMAP)diet(LFD)was introduced for the next6 wk while continuing the registration.Though a small sample size a significant improvement in disease activity(IBS-SSS)was observed during both the control period,median:278(range:122-377),P=0.02,and subsequently during the LFD period,median:151(range:29-334),P<0.01.The IBS-QoL solely changed significantly during the LFD period,median:67(37-120),P<0.01.The significant reduction in disease activity during the control period shows a positive effect of the web-application on IBS symptoms when presented as a'traffic light'.However adding the diet reduced IBSSSS to<150,inactive to mild symptoms.In the future results from larger scale trials are awaited.Natalia Pedersen Zsuzsanna Vegh Johan Burisch Lisbeth Jensen Dorit Vedel Ankersen Maria Felding Nynne Nyboe Andersen Pia Munkholm 2014World Journal of Gastroenterology2014,20,21:7
6The burden of inflammatory bowel disease in Europe显示文摘Johan Burisch Tine Jess Matteo Martinato Peter L. Lakatos 2013Journal of Crohn’s and Colitis2013,,:5
7Inflammatory bowel disease epidemiology显示文摘Johan Burisch Pia Munkholm 2013Current Opinion in Gastroenterology2013,,4:3
8Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial显示文摘BACKGROUND The optimal way to home-monitor patients with inflammatory bowel disease(IBD)for disease progression or relapse remains to be found.AIM To determine whether an electronic health(eHealth)screening procedure for disease activity in IBD should be implemented in clinical practice,scheduled every third month(3M)or according to patient own decision,on demand(OD).METHODS Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions(3M vs OD).Both intervention arms were screening for disease activity,quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M.Disease activity was assessed using home measured fecal calprotectin(FC)and a disease activity score.RESULTS In total,102 patients were randomized(n=52/503M/OD)at baseline,and 88 patients completed the 1-year study(n=433M;n=45 OD).No difference in the two screening procedures could be found regarding medical compliance(P=0.58),fatigue(P=0.86),quality of life(P=0.17),mean time spent in remission(P>0.32),overall FC relapse rates(P=0.49),FC disease courses(P=0.61),FC time to a severe relapse(P=0.69)and remission(P=0.88)during 1 year.Median(interquartile range)numbers of FC home-monitoring test-kits used per patient were significantly different,3M:6.0(5.0-8.0)and OD:4.0(2.0-9.0),P=0.04.CONCLUSION The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission.However,the OD group used fewer FC home testkits per patient.Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice.Dorit Vedel Ankersen Petra Weimers Dorte Marker Mette Bennedsen Sanaz Saboori Kristine Paridaens Johan Burisch Pia Munkholm 2019World Journal of Gastroenterology2019,25,40:2
9Inflammatory bowel disease epidemiology 显示文摘Johan Burisch and Pia Munkholm 2013Gun' Opin Gastroenteml2013,29,4:1
10Polymorphisms in the inflammatory pathway genes TLR2,TLR4,TLR9,LY96,NFKBIA,NFKBl,TNFA,TNFRSF1A,IL6R,IL10,II23R,PTPN22,and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort显示文摘Bank S Skytt Andersen P Burisch J 2014PLoS One2014,9,6:1
11Test Length and Validity Revisited 显示文摘Burisch M 1997European Journal of Personality1997,,11:1
12A longitudinal study of burnout:The relative importance of dispositions and experience显示文摘Burisch M 2002Work And Stress2002,16,1:1
13Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups显示文摘AIM To summarise the current literature and define patterns of disease in migrant and racial groups.METHODS A structured key word search in Ovid Medline and EMBASE was undertaken in accordance with PRISMA guidelines. Studies on incidence, prevalence and disease phenotype of migrants and races compared with indigenous groups were eligible for inclusion. RESULTS Thirty-three studies met the inclusion criteria. Individual studies showed significant differences in incidence, prevalence and disease phenotype between migrants or race and indigenous groups. Pooled analysis could only be undertaken for incidence studies on South Asians where there was significant heterogeneity between the studies [95% for ulcerative colitis(UC), 83% for Crohn's disease(CD)]. The difference between incidence rates was not significant with a rate ratio South Asian: Caucasian of 0.78(95%CI: 0.22-2.78) for CD and 1.39(95%CI: 0.84-2.32) for UC. South Asians showed consistently higher incidence and more extensive UC than the indigenous population in five countries. A similar pattern was observed for Hispanics in the United States. Bangladeshis and African Americans showed an increased risk of CD with perianal disease. CONCLUSION This review suggests that migration and race influence the risk of developing inflammatory bowel disease. This may be due to different inherent responses upon exposure to an environmental trigger in the adopted country. Further prospective studies on homogenous migrant populations are needed to validate these observations, with a parallel arm for in-depth investigation of putative drivers.Ravi Misra Omar Faiz Pia Munkholm Johan Burisch Naila Arebi 2018World Journal of Gastroenterology2018,24,3:1
14East - West gradient in the incidence of inflammatory bowel dis- ease in Europe: the ECCO -EpiCom inception cohort显示文摘Burisch J Pedersen N Cukovic - Cavka S 2014Gut2014,63,4:1
15Ethnic differences in inflammatory bowel disease: Results from the United Kingdom inception cohort epidemiology study显示文摘BACKGROUND The current epidemiology of inflammatory bowel disease(IBD)in the multiethnic United Kingdom is unknown.The last incidence study in the United Kingdom was carried out over 20 years ago.AIM To describe the incidence and phenotype of IBD and distribution within ethnic groups.METHODS Adult patients(>16 years)with newly diagnosed IBD(fulfilling Copenhagen diagnostic criteria)were prospectively recruited over one year in 5 urban catchment areas with high South Asian population.Patient demographics,ethnic codes,disease phenotype(Montreal classification),disease activity and treatment within 3 months of diagnosis were recorded onto the Epicom database.RESULTS Across a population of 2271406 adults,339 adult patients were diagnosed with IBD over one year:218 with ulcerative colitis(UC,64.3%),115 with Crohn's disease(CD,33.9%)and 6 with IBD unclassified(1.8%).The crude incidence of IBD,UC and CD was 17.0/100000,11.3/100000 and 5.3/100000 respectively.The age adjusted incidence of IBD and UC were significantly higher in the Indian group(25.2/100000 and 20.5/100000)compared to White European(14.9/100000,P=0.009 and 8.2/100000,P<0.001)and Pakistani groups(14.9/100000,P=0.001 and 11.2/100000,P=0.007).The Indian group were significantly more likely to have extensive disease than White Europeans(52.7%vs 41.7%,P=0.031).There was no significant difference in time to diagnosis,disease activity and treatment.CONCLUSION This is the only prospective study to report the incidence of IBD in an ethnically diverse United Kingdom population.The Indian ethnic group showed the highest age-adjusted incidence of UC(20.5/100000).Further studies on dietary,microbial and metabolic factors that might explain these findings in UC are underway.Ravi Misra Jimmy Limdi Rachel Cooney Samia Sakuma Matthew Brookes Edward Fogden Sanjeev Pattni Naveen Sharma Tariq Iqbal Pia Munkholm Johan Burisch Naila Arebi 2019World Journal of Gastroenterology2019,25,40:1
16Challenges of precision assembly with a miniaturized robot显示文摘BURISCH A RAATZ A HESSELBACH J 2010IFIP Advances in Information and Communication Technology2010,315,5:1
17You don 1 always get what you pay for: Measuring depres- sion with short and simple versus long and sophisticated scales 显示文摘Burisch M 1984Journal of Research in Personality1984,18,1:1
18The burden of inflammatory bowel disease in Europe显示文摘Johan Burisch Tine Jess Matteo Martinato Peter L. Lakatos 2013Journal of Crohn’s and Colitis2013,,:1
19E-health empowerspatients with ulcerative colitis:a randomised controlled trialof the web-guided 'constant-care,approach显示文摘Elkjaer M Shuhaibar M Burisch J 2010Gut2010,59,12:1
20Approaches to personality inventory construction 显示文摘BURISCH B 1984Am Psych1984,39,3:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费